AgomAb Therapeutics NV
AGMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002020932
No open-market purchases or sales by AgomAb Therapeutics NV insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in AgomAb Therapeutics NV as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 34
- +2 vs. Q1 2026
- Shares held
- 26.0M
- +2.60M (+11.1%) vs. Q1 2026
- Total value
- $337.0M
- +$91.7M (+37.4%) vs. Q1 2026
- New holders
- 9
- 4 more added
- Sold out
- 7
- 6 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AGMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $337.0M |
| Q1 2026 | 32 | $245.3M |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding AgomAb Therapeutics NV; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 2 | $26 | 0.00% | 00.0% | Unchanged |
| Caitong International Asset Management Co., Ltd | 2 | $26 | 0.00% | +2 | New |
| Larson Financial Group LLC | 698 | $9.06K | 0.00% | +698 | New |
| BNP Paribas Arbitrage, SA | 754 | $9.79K | 0.00% | +754 | New |
| Morgan Stanley | 1,200 | $15.6K | 0.00% | −1,825−60.3% | Reduced |
| GAMMA Investing LLC | 1,344 | $17.4K | 0.00% | +1,344 | New |
| UBS Group AG | 2,128 | $27.6K | 0.00% | −4,309−66.9% | Reduced |
| Citigroup Inc | 9,496 | $123.3K | 0.00% | +9,496 | New |
| XTX Topco Ltd | 10,271 | $133.3K | 0.00% | +10,271 | New |
| Goldman Sachs Group Inc | 11,800 | $153.2K | 0.00% | −23,939−67.0% | Reduced |
| HRT Financial LP | 17,075 | $221.0K | 0.00% | −6,651−28.0% | Reduced |
| Two Sigma Investments, LP | 18,072 | $234.6K | 0.00% | +3,831+26.9% | Added |
| Quadrature Capital Ltd | 20,461 | $265.6K | 0.00% | +20,461 | New |
| Burkehill Global Management, LP | 35,000 | $454.3K | 0.02% | 00.0% | Unchanged |
| Sectoral Asset Management Inc | 43,500 | $564.6K | 0.39% | 00.0% | Unchanged |
| Seven Grand Managers, LLC | 47,600 | $617.8K | 0.02% | −152,400−76.2% | Reduced |
| Bellevue Group AG | 49,248 | $639.2K | 0.01% | −752−1.5% | Reduced |
| Alps Advisors Inc | 49,984 | $648.8K | 0.00% | +49,984 | New |
| Pfizer Inc | 75,000 | $1.04M | 0.61% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 192,740 | $2.50M | 0.05% | +192,740 | New |
| Siren, L.L.C. | 411,250 | $5.34M | 0.11% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 600,000 | $7.79M | 0.12% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 600,000 | $7.79M | 0.64% | 00.0% | Unchanged |
| Standard Life Aberdeen plc | 846,695 | $11.0M | 0.02% | +139,039+19.6% | Added |
| FMR LLC | 1,458,677 | $18.9M | 0.00% | 00.0% | Unchanged |
| Andera Partners | 1,538,702 | $20.0M | 9.67% | 00.0% | Unchanged |
| Casdin Capital, LLC | 1,550,000 | $20.1M | 1.01% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 1,568,188 | $20.4M | 1.23% | +368,188+30.7% | Added |
| Federated Hermes, Inc. | 1,618,000 | $21.0M | 0.03% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 2,053,233 | $26.7M | 0.64% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 2,465,348 | $32.0M | 1.64% | 00.0% | Unchanged |
| Redmile Group, LLC | 2,733,926 | $35.5M | 2.38% | +2,577,676+1,649.7% | Added |
| Sanofi | 2,783,096 | $36.1M | 6.76% | 00.0% | Unchanged |
| EQT Fund Management S.a r.l. | 5,141,992 | $66.7M | 7.74% | 00.0% | Unchanged |
| LMR Partners LLP | 0 | $0 | 0.00% | −300,000−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −95,233−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −75,000−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −35,000−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −15,326−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −12,794−100.0% | Sold out |